Thus, investigation has focused on therapies directed at immune targets, resulting in the main approved therapeutic agent for melanoma used nowadays, ipilimumab (human monoclonal antibody (IgG1k) against the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4)) [3,4,5]. The gene discussed is CTLA4; the disease is melanoma.